EU approves Roche’s Cotellic in combo therapy against skin cancer

Swiss drugmaker Roche's logo is seen at their headquarters in Basel, SwitzerlandThe European Union gave its green light to Roche's Cotellic for use in combination with the drug Zelboraf against advanced melanoma, the company said on Wednesday. Roche is counting on Cotellic to help it revive flagging sales of five-year-old Zelboraf, which dropped 25 percent during the first nine months of 2015. It has been under intense pressure from rivals' drugs as the standard of care moves to combination therapy.



Medications/Drugs News Headlines – Yahoo! News

Pharmaceutical Stocks

[stock-ticker]

© 2017 Drugs News All rights reserved.       Privacy Policy       Contact Us